News and Trends 22 Sep 2022 New study shows how prostate cancer may start Researchers at the University of East Anglia in the U.K. say they have made an important discovery about how prostate cancer may start to develop. A new study published in Molecular Oncology reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Sep 2022 The 5 hottest biotech companies making waves in Israel Despite its small population, Israel hosts a high concentration of startups. Here’s a collection of the hottest biotech companies raising big cash in the Middle Eastern nation. Historically, Israel’s biotech industry has been viewed as secondary to its thriving medtech scene. However, in spite of a population of just 9 million people, the nation has […] September 21, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […] September 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 NodThera reveals positive results for inflammasome inhibitors Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249. A phase 1 study has been completed for NT-0796, confirming brain penetration with excellent pharmacokinetic (PK) and pharmacodynamic (PD) profiles and for NT-0249, dosing of the phase 1 single ascending dose cohorts has been completed, […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Quinten Health closes financing round to advance disease modeling platforms A financing round to advance disease modeling platforms and virtual twins in real world has been closed by Quinten Health. The company that works in real-world data science, artificial intelligence (AI) and machine learning (ML) for precision care, made the announcement today (September 21). The round is part of the Quinten Group’s €14 million ($13.9 […] September 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 FDA clears Cellenkos ALS drug for trial Cellenkos, Inc., a clinical stage biotech company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a phase 1 safety study followed by a phase 1b randomized, double blind, placebo control trial of CK0803, neurotrophic allogeneic Treg cells, in patients with amyotrophic lateral sclerosis […] September 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Anina – reshaping the future of food by upcycling rejected vegetables Two industrial design students were so concerned by the huge amounts of perfectly good fresh produce being wasted, they spent two years working on a healthy solution. Esti Brantz and Meydan Levy noticed that fruit and veg was getting tossed in the trash due to cosmetic reasons such as size, shape, color differences, or […] September 21, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Poolbeg to investigate melioidosis vaccine candidate Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease for which there is no current approved vaccine available.The vaccine candidate, which is being developed by Poolbeg Pharma as POLB 003, was invented following many […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Hoag’s high hopes for new drug with Alzheimer’s disease trial Hoag’s Pickup Family Neurosciences Institute is initiating a clinical trial for what it says is a promising new investigational treatment for Alzheimer’s disease (AD). The phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. Hoag is seeking individuals who have memory problems to […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research The Novo Nordisk Foundation has awarded a grant of $200 million to establish the first full-scale quantum computer for the development of new medicines. The computer will also provide new insights into climate change and the green transition, which is not possible with classical computers today. The computer could be located in a data center, […] September 21, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 New Bio Studio program collaboration looks to create life science start-ups The BioInnovation Institute (BII), has entered a collaboration with Imperial College London in the U.K. to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research to benefit people and society. Based in Denmark, the BII is an international commercial, […] September 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 ten23 health completes superstructure of new sterile production facility ten23 health, a global contract development and manufacturing organization (CDMO) has completed the superstructure of its new sterile manufacturing facility. The existing facility of ten23 health’s swissfillon AG company in Visp already offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and commercial supplies, in collaboration with ten23 health’s development center in […] September 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email